<DOC>
	<DOCNO>NCT01191983</DOCNO>
	<brief_summary>This single arm , open label study ass efficacy , safety tolerability Mircera ( methoxy polyethylene glycol-epoetin beta ) treatment renal anemia patient chronic kidney disease secondary diabetes . Patients dialysis currently treat erythropoiesis stimulate agent receive Mircera subcutaneously every 4 week . The start dose 1.2 mcg/kg Mircera adjust accord haemoglobin level . Anticipated time study treatment 28 week .</brief_summary>
	<brief_title>A Study Mircera ( Methoxy Polyethylene Glycol-Epoetin Beta ) Treatment Chronic Renal Anaemia Patients With Diabetic Nephropathy</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Diabetic Nephropathies</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Adult patient , &gt; /= 18 year age Diabetic nephropathy Chronic renal anaemia stage IIIIV chronic kidney disease Not dialysis expect require dialysis within next 6 month Not receive erythropoiesis stimulate agent ( ESA ) 2 month prior study Adequate iron status Transfusion red blood cell previous 2 month Known clinical suspicion pure red cell aplasia Hypersensitivity recombinant human erythropoietin , polyethylene glycol constituent study medication Haemoglobinopathy Significant acute chronic bleeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>